Novartis licensed PTC's PTC518 Huntington's disease program and related molecules and will pay $1 billion upfront as well as other costs.

FDA’S DAY AT SCOTUS — Don’t expect the Supreme Court to take a sledgehammer to the FDA’s ability to regulate tobacco.

Shares of PTC Therapeutics Inc. climbed nearly 1% pre-market Tuesday, poised to extend their rally to levels last seen in ...

The potential $2.9 billion deal stands the New Jersey company in good stead after recent disappointing results in its ALS ...

PTC Therapeutics inks global license and collaboration agreement with Novartis for PTC518 Huntington's disease programme: Warren, New Jersey Tuesday, December 3, 2024, 14:00 Hrs [ ...

Basel: Novartis has announced that it has entered into a global license and collaboration agreement with PTC Therapeutics for ...

Wells Fargo keeps an Overweight rating and $68 price target on PTC Therapeutics (PTCT). Investors had been undervaluing the potential value of ...

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG ...

PTC Therapeutics Inc. said a “highly competitive process with several parties involved” led to the deal centered on the ...

Novartis will pay PTC Therapeutics up to $2.9 billion in a licensing deal for its Huntington's treatment. PTC Therapeutics stock surged.

Novartis will partner with PTC Therapeutics to develop PTC’s PTC518 Huntington's disease program and an unspecified number of related molecules, through an up-to-$2.9 billion exclusive global license ...

A roundup of significant health updates globally includes Sanofi's major investment in China, New Zealand suspending poultry ...